Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01118962 · ClinicalTrials.gov registry record · Phase 2
Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy
A Phase 2 study of Epilepsy, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 19
- Study locations
NCT01118962: Completed Phase 2 study of Epilepsy, sponsored by UCB Biosciences.
NCT01118962 is a Phase 2 study of Epilepsy that has completed, run by UCB Biosciences. The registered enrollment target is 39 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (96% lower). The trial reports 19 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01118962, a Phase 2 study of Epilepsy, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose is to obtain data on the safety and seizure frequency associated with long-term oral Lacosamide for uncontrolled primary generalized tonic-clonic (PGTC) seizures in subjects with idiopathic generalized Epilepsy. Additionally, to allow subjects who have completed SP0961 (NCT01118949) to continue to receive Lacosamide.
Conditions Studied
Interventions
- DRUG Lacosamide
Study Locations (19)
Kentucky
- 605 - Lexington
- 616 - Louisville
Arizona
- 603 - Phoenix
Arkansas
- 602 - Little Rock
Colorado
- 628 - Aurora
Georgia
- 613 - Atlanta
Idaho
- 617 - Boise
Indiana
- 614 - Fort Wayne
Maine
- 619 - Scarborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
What the finished NCT01118962 record still lists
NCT01118962 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Lacosamide is the first listed.
NCT01118962 lists 19 locations in 18 states (Kentucky, Arizona, Arkansas).
Frequently Asked Questions
What is clinical trial NCT01118962 about?
NCT01118962 is a clinical study titled "Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy". The purpose is to obtain data on the safety and seizure frequency associated with long-term oral Lacosamide for uncontrolled primary generalized tonic-clonic (PGTC) seizures in subjects with idiopathic generalized Epilepsy. Additionally, to allow subjects who have completed SP0961 (NCT01118949) to c...
What is the current status of trial NCT01118962?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2010-08. Estimated completion is 2012-10.
What conditions does trial NCT01118962 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT01118962?
The interventions under investigation include: Lacosamide (DRUG).
Who is sponsoring clinical trial NCT01118962?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01118962 being conducted?
This trial has 19 study locations across Arizona, Arkansas, Colorado, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01118962's enrollment target sits among peer trials
39 101st of 160 higher than 59 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
RECRUITING · Phase 2
-
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
RECRUITING · Phase 2
-
RNS System LGS Feasibility Study
ACTIVE NOT RECRUITING · Phase 2
-
Study of an External Responsive Neurostimulator System on Epileptiform Activity
COMPLETED · Phase 2
-
Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI
COMPLETED · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia